3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
15
Breast Neoplasms
14
Sarcoma
11
Squamous Cell Carcinoma of Head and Neck
10
Glioblastoma
10
Esophageal Neoplasms
9
Rectal Neoplasms
8
Stomach Neoplasms
7
Urinary Bladder Neoplasms
6
Neoplasms
6
Carcinoma, Hepatocellular
6
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Brain Neoplasms
5
Oropharyngeal Neoplasms
4
Lung Neoplasms
4
Hypopharyngeal Neoplasms
4
Head and Neck Neoplasms
4
Glioma
4
Colonic Neoplasms
4
Recurrence
3
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Mouth Neoplasms
3
Melanoma
3
Astrocytoma
3
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Skin Neoplasms
2
Interventions
pembrolizumab
16
Nivolumab
15
Ipilimumab
12
cemiplimab
10
aldesleukin
6
Interleukin-2
6
Cyclophosphamide
6
fludarabine
5
fludarabine phosphate
4
encorafenib
4
binimetinib
4
Blood Specimen Collection
4
avelumab
3
Sirolimus
3
trametinib
2
spartalizumab
2
lifileucel
2
dabrafenib
2
atezolizumab
2
Vemurafenib
2
Surgical Procedures, Operative
2
Specimen Handling
2
Radiotherapy
2
Prednisone
2
Niacinamide
2
Exercise
2
Everolimus
2
Dermoscopy
2
Biopsy
2
urelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
Surgical Procedures, Operative
×
1 year
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled
NCT03534947
2025-12-16
SONIB
Melanoma Institute Australia
Phase 2
Completed
16 enrolled